Borea Therapeutics

Borea Therapeutics, established as an academic spin-off from the University of Ferrara and Vita-Salute San Raffaele University, is a biotechnology firm concentrated on developing advanced gene therapy solutions. The company was co-founded by a team of prominent scientists: an Associate Professor of Pharmacology at the University of Ferrara, a Group Leader at the San Raffaele Telethon Institute for Gene Therapy, a Full Professor of Pharmacology at the University of Ferrara, and an Associate Professor of Medical Genetics at the University of Naples. Their collective expertise in pharmacology, molecular biology, and gene therapy forms the scientific foundation of the company's operations.

The core of Borea's business lies in its proprietary drug discovery platform, which engineers next-generation Adeno-Associated Virus (AAV) vectors for gene therapy applications. These vectors are designed to overcome the limitations of current gene therapy methods by offering enhanced efficiency and specificity in targeting desired cells and tissues. The company's platform utilizes a knowledge-based approach to capsid design, the protein shell of the virus that determines its target, allowing for the creation of customized vectors for specific therapeutic needs. This capability positions Borea to address a range of genetic and acquired diseases that are currently undertreated.

Borea Therapeutics operates on a business-to-business model, collaborating with pharmaceutical and biotechnology companies. Revenue generation is structured around providing these partners with its custom-designed AAV vectors. These collaborations are aimed at advancing the development of novel gene therapies from the preclinical stage through to clinical application. By focusing on the critical delivery component of gene therapy, Borea aims to enable the creation of more effective and safer treatments for a variety of medical conditions.

Keywords: gene therapy, AAV vectors, drug discovery, biotechnology, academic spin-off, capsid design, pharmacology, molecular biology, genetic diseases, preclinical research